BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Duchenne muscular dystrophy clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for Duchenne muscular dystrophy: 57 (32 sponsors; 6 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 7.9, rank 81 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 3, Phase 2 30, Phase 3 11, Phase 4 3, N/A 8.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Sarepta Therapeutics, Inc. SRPT6P3 2, P4 1, NA 2, P1 100
Italfarmaco3P2 1, P3 200
NS Pharma, Inc.5P3 1, P4 1, P2 311
REGENXBIO Inc. RGNX3NA 2, P3 100
Avidity Biosciences, Inc.2P2 1, P3 101
Capricor Inc. CAPR2P3 1, P2 100
Dyne Therapeutics DYN2P3 1, P2 110
Solid Biosciences Inc. SLDB2P3 1, P2 101
Pfizer PFE1P3 100
Edgewise Therapeutics, Inc. EWTX3P2 302
Entrada Therapeutics, Inc. TRDA3P2 310
BioMarin Pharmaceutical BMRN2P2 201
Hoffmann-La Roche2P2 201
Satellos Bioscience, Inc. MSLE2P2 201
Wave Life Sciences USA, Inc. WVE2P2 200
AO GENERIUM new entrant1P2 110
Belief BioMed (Beijing) Co., Ltd1P2 100
Catalyst Pharmaceuticals, Inc. CATL1NA 100
Daiichi Sankyo Co., Ltd.1P2 101
Grünenthal GmbH new entrant1P2 110
HuidaGene Therapeutics Co., Ltd.1EARLY_P1 100
Insmed Gene Therapy LLC INSM1P1 100
ITF Therapeutics LLC1NA 100
Keros Therapeutics, Inc. KROS new entrant1P2 110
MED Institute Inc.1P2 100

New-entrant sponsors: AO GENERIUM, Grünenthal GmbH, Keros Therapeutics, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P2Edgewise Therapeutics, Inc. EWTXNCT05540860 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Duchenne Muscular Dystrophyactive not recruiting76
2027-01-31 est.P2Daiichi Sankyo Co., Ltd.NCT04433234 Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyDuchenne Muscular Dystrophyactive not recruiting8

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2027-01-21PDUFA date (company-disclosed)pendingDyne Therapeutics, Inc. DYNrostudirsenPDUFA January 21, 2027 - Dyne Therapeutics, Inc. (rostudirsen)
2026-11-22PDUFA date (company-disclosed)pendingCAPRICOR THERAPEUTICS, INC. CAPRPDUFA November 22, 2026 - CAPRICOR THERAPEUTICS, INC.
2026-07-29FDA AdComheldCapricor, Inc. CAPRAdCom 2026-07-29: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125842

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-18 est.P2Hoffmann-La RocheNCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophyactive not recruiting30
2026-11-03P1/P2Solid Biosciences Inc. SLDBNCT03368742 Microdystrophin Gene Transfer Study in Adolescents and Children With DMDDuchenne Muscular Dystrophycompleted12
2026-10 est.P1/P2Wave Life Sciences USA, Inc. WVENCT04906460 Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)Duchenne Muscular Dystrophyactive not recruiting25
2026-09-07P2Edgewise Therapeutics, Inc. EWTXNCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Becker Muscular Dystrophycompleted244
2026-09-07P3Sarepta Therapeutics, Inc. SRPTNCT03992430 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Muscular Dystrophy, Duchennecompleted160
2026-09 est.P2/P3REGENXBIO Inc. RGNXNCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophyactive not recruiting65
2026-07-23P3Avidity Biosciences, Inc.NCT06411288 Global Study of Del-desiran for the Treatment of DM1DM1; Myotonic Dystrophy; Myotonic Dystrophy 1; Myotonia; Myotonic Dystrophy Type 1 (DM1); Dystrophy completed159
2026-06-18P3Taiho Pharmaceutical Co., Ltd.NCT04587908 A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD)Duchenne Muscular Dystrophycompleted104

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Duchenne muscular dystrophy"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.